Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding

Raksha Jain, Alvit Wolf, Michal Molad, Jennifer Taylor-Cousar, Charles R.Esther Jr, Michal Shteinberg

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Elexacaftor-tezacaftor-ivacaftor (ETI) is known to pass through the placenta and into breast milk in mothers who continue on this therapy while pregnant and breast feeding. Toxicity studies of ivacaftor in rats demonstrated infant cataracts, but cataracts were not reported in human infants exposed to ivacaftor. We describe 3 cases of infants exposed to elexacaftor-tezacaftor-ivacaftor (ETI) in utero and while breast feeding who were found to have bilateral congenital cataracts within six months of birth. None of the infants had significant visual impairment from the cataracts nor any report of elevated liver function testing. These data highlight the need to counsel females who continue ETI throughout pregnancy and while breast feeding to consider cataract screen for their infants.

Original languageEnglish (US)
Pages (from-to)1074-1076
Number of pages3
JournalJournal of Cystic Fibrosis
Volume21
Issue number6
DOIs
StatePublished - Nov 2022

Keywords

  • Breast feeding
  • Cataract
  • Elexacaftor-tezacaftor-ivacaftor
  • Pregnant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding'. Together they form a unique fingerprint.

Cite this